newsfilter
← Latest News
Business Wire·

Phase 2 Dose‑Ranging Clinical Trial Results of CTP‑543 in Patients with Alopecia Areata published in the Journal of the American Academy of Dermatology

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced the publication of safety and efficacy data from the randomized, double-blind, placebo-controlled dose-ranging Phase 2 clinical trial for CTP‑543 in the Journal of the American Academy of Der